Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00545662 · ClinicalTrials.gov registry record · Phase 3
Study of Citicoline for the Treatment of Traumatic Brain Injury (COBRIT)
A Phase 3 study, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,213
- Enrollment target
NCT00545662 is a Phase 3 study that was terminated before completion, run by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The registered enrollment target is 1,213 participants.
The verdict
NCT00545662, a Phase 3 study, was terminated before completion, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,213 participants
- Enrollment target
Study Summary
The Citicoline Brain Injury Treatment (COBRIT) is a randomized, double-blind, placebo controlled, multi-center trial of the effects of 90 days of citicoline on functional outcome in patients with complicated mild, moderate and severe traumatic brain injury.
Interventions
- DRUG Placebo
- DRUG citicoline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,213 participants |
| Start Date | 2007-07 |
| Est. Completion | 2011-05 |
| Phase | Phase 3 |
Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)305 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00545662
The ClinicalTrials.gov registry entry for NCT00545662 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,213 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00545662 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00545662 about?
NCT00545662 is a clinical study titled "Study of Citicoline for the Treatment of Traumatic Brain Injury (COBRIT)". The Citicoline Brain Injury Treatment (COBRIT) is a randomized, double-blind, placebo controlled, multi-center trial of the effects of 90 days of citicoline on functional outcome in patients with complicated mild, moderate and severe traumatic brain injury.
What is the current status of trial NCT00545662?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,213 participants. The study started on 2007-07. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00545662?
The interventions under investigation include: Placebo (DRUG), citicoline (DRUG).
Who is sponsoring clinical trial NCT00545662?
This trial is sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.